The prospect that interferon alfa might be shown to have a role in the management of age-related macular degeneration' is given further support in two papers in this issue of the journal.The exact mechanism involved remains unclear but there is in vitro evidence that interferon alfa inhibits endothelial cell proliferation and migration. In experimental animals it has been shown to inhibit leucocyte induced angiogenesis and its role in the management of life threatening haemangiomas in children is also recognised. Converted into the management of age-related macular degeneration it might be hoped that it would influence the developing neovascular membrane thereby avoiding foveolar destruction and consequent visual loss.
These studies report interferon alfa treatment of patients with membranes within the avascular zone. Although the number of patients with neovascular membranes showing improvement, in terms of visual acuity, membrane size, or angiographic appearance is relatively small the fact that nine out of 50 did show early benefit is noteworthy. Equally, 29 out of 50 retained their pretreatment acuity and 17 out of 50 showed no change in the clinical appearance. The treatment period was short in both studies (4) (5) (6) 
Choice in local anaesthesia
A recent Medline database search selected more than 100 articles in the last 3 years relevant to local anaesthesia in ophthalmic surgery. Techniques described included retrobulbar, peribulbar, subconjunctival, one quadrant, and four quadrant sub-Tenon's injections, and their variants. Phacoemulsification using topical anaesthesia only has also been reported, and the anaesthetic solution has been 'doctored' to reduce stinging.' What should the ophthalmic surgeon in training derive from this wealth (or minefield) of data?
The complications of local anaesthesia have been well documented. Studies using computed tomography2 and magnetic resonance imaging3 have improved our understanding of anatomical relations in the orbit, though they have yet to prove their value in terms of lowered complication rates. Other obvious topics for investigation have been the efficacy of anaesthesia and akinesia, safety, and long term morbidity. However, many papers can be criticised for inadequate scientific methodology, particularly with regard to assessment of akinesia and pain.
In this issue of the journal, Ali-Melkkila et al report on the comparison of three techniques of local anaesthesia which raises several important issues. The blocks were administered by anaesthetists rather than the surgeon. Is this ideal? There may be a clear conflict between improving 'turnover time' in theatre and the desirability ofclose quarter observation of the initial reaction to pain stimuli and periocular manipulation. Personal administration of the block promotes the best chance of observing orbital haemorrhage or other complications before draping the patient and incising the eye.
The use of a scoring system for akinesia is desirable in a research setting, but preset criteria seem to have resulted in reblock rates (11% to 19%) that are high in our experience. The norm in usual practice is close to 0%. We look forward to studies using peroperative video monitoring and subsequent assessment by an independent observer. It is likely that surgeons quickly develop a personal tolerance to eye movement that is preferable to running the gauntlet of peribulbar injection again. The Hutton.7 The essential message is that pulse oximetry is a poor measure of hypoventilation when the concentration ofinspired oxygen is high. The surgeon should consider whether oxygen supplementation under the drapes is strictly necessary, and whether transparent drapes will assist in observation of chest wall movement.
The administration of local anaesthesia has always been more than just deciding on the right place to inject. Decisions range from costs, time efficiency, safety, efficacy, and monitoring to postoperative analgesia. It is unlikely that any single approach will be ideal. However, where a peribulbar technique is chosen, it would make sense to use the medial compartment of the orbit as the site of the second injection as it works well, does not run the risk of damage to the trochlea, and reduces the risk of globe perforation.
